QIAGEN HPV test improves cervical cancer control

Researchers with QIAGEN said a recent study has shown that Latin American women who used its human papillomavirus test showed improved cervical cancer control when compared to regular cytology testing.

Dr. Eduardo Lazcano-Ponce, lead study author of the study and executive director of the Population Health Research Center at the National Institute of Public Health in Cuernavaca, Mexico, said that approximately 50,000 women participated in the study, which was one of the first and largest of its kind.

“Population based programs using HR-HPV testing can improve cervical cancer prevention and control in Mexican and other populations where cytological screening is inadequate for detecting the precursors of cervical cancer,” Lazcano-Ponce said. “Our findings offer strong evidence to justify implementation of population-based programs using HPV DNA screening.”

The study subjects received both Pap testing and HPV DNA testing using QIAGEN's digene HPV Test. According to the study, results showed the clinical sensitivity of HPV DNA testing using the digene HPV test was more than double that of cytology, detecting 93.3 percent of precancerous and cancerous lesions over the 40 percent detected by cytology.

“Cervical cytology screening has greatly reduced invasive cervical cancer incidence in industrialized countries," Lazcano-Ponce said. "However, this approach requires repeated Pap testing at short intervals, confirmation of abnormalities by colposcopy, biopsy collection and histological confirmation in order to treat cancer precursor lesions. This kind of program is highly expensive and not affordable by many developing countries.

“New prevention alternatives for cervical cancer are needed, with greater sensitivity, to aid in improving cervical cancer screening...HPV testing has proven to be a highly sensitive screening tool for cervical cancer precursor lesions and has been successfully used in diverse clinical settings; clinical trials and epidemiological studies have demonstrated the suitability of testing for HR-HPV in population based programs.”